Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05061_nanopub.RA4FC9N9s1EmvdFw_w9c4t_tMeq2yYbLAoHgV6BWK8Hkw#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05061 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05061 label "GFT14 [drugbank:DB05061]" assertion.
- drugbank:DB05061 seeAlso DB05061 assertion.
- drugbank:DB05061 description "GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease. GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) and on other risk factors such as hypertension or diabetes. Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). The risks of medical interaction are weak and GFT14 may be easily combined with statins or other antidiabetic molecules (glitazones)." assertion.
- drugbank:DB05061 identifier "drugbank:DB05061" assertion.
- drugbank:DB05061 title "GFT14" assertion.
- drugbank:DB05061 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05061 drugbank_vocabulary:drugbank-id "DB05061" assertion.
- drugbank:DB05061 bio2rdf_vocabulary:x-identifiers.org DB05061 assertion.
- drugbank:DB05061 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05061" assertion.
- drugbank:DB05061 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05061 bio2rdf_vocabulary:identifier "DB05061" assertion.